Treatment options for patients with advanced cutaneous melanoma expanded significantly with FDA approval of immune-checkpoint blockade drugs and BRAF/MEK targeting signal transduction inhibitors. The gene discussed is MAP2K7; the disease is cutaneous melanoma.